Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses.

Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. 

Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio.

Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.


Biotechnology

Life Sciences

Therapeutics

Imcyse SA

Denis Bedoret

Jean van Rampelbergh

Antoon van Oosterhout

Hugues Wallemacq

Andrew Mackie

The Scientific Research and Development team at Imcyse SA is responsible for advancing the company's immunotherapy pipeline, including the development and optimization of Imotope™ technology. They conduct preclinical and clinical research to evaluate the efficacy and safety of novel therapies, such as IMCY-0098 for type 1 diabetes. The team collaborates closely on experimental design, data analysis, and regulatory submissions to push forward the company's mission of curing autoimmune diseases.

Scientific Research and Development

Management

Leadership Team

Scientific Research and Development

About

Team members

Other teams at Imcyse SA

Management

Leadership Team